Within the weeks across the 2026 annual assembly of the American Society of Medical Oncology, my telephone saved humming with signals about GLP-1 medication and most cancers. The headlines have been all over the place – from NPR and The Washington Submit to Substack and heated exchanges on social media – all circling the similar declare: Ozempic may decrease the danger of most cancers.
At the back of the ones headlines is an actual wave of research, involving thousands and thousands of sufferers. I’m a health care provider and scientific epidemiologist, and my staff and I design and interpret those similar forms of research that check what broadly used medication if truth be told do.
The thrill round the concept GLP-1 medication can save you most cancers is operating neatly forward of the proof. No longer mistaken, essentially. Simply no longer but earned.
Most cancers is one of the toughest issues to review, as a result of it’s not one illness however greater than 100. Breast most cancers, lung most cancers and blood cancers aren’t permutations of the similar illness; each and every has its personal distinct biology and its personal mixture of genetic, environmental and behavioral dangers.
A unmarried drug by no means will get one verdict on the way it impacts most cancers. It will get 100, elevating the danger of a few, decreasing it for others and leaving maximum untouched.
The early most cancers issues
Earlier than the present buzz that GLP-1 medication may just cut back most cancers possibility, the concern ran in the wrong way: that they may carry most cancers possibility.
Researchers have been firstly interested in thyroid most cancers. Research in rodents discovered that Ozempic brought about thyroid C cellular tumors, which is why U.S. regulators added a black field caution in June 2026 to the drug that advises in opposition to its use amongst the ones with a private or circle of relatives historical past of connected stipulations.
However rodents aren’t folks. Human thyroid C cells are much less delicate to GLP-1 medication in comparison to rodent C cells as a result of they’ve a long way fewer GLP-1 receptors. Lengthy-term research in monkeys didn’t display the similar unusual thyroid cellular enlargement noticed in rodents.
A 2025 research of information from 93 scientific trials discovered no transparent hyperlink between taking sure GLP-1 medication and thyroid most cancers. Ecu regulators reached the similar conclusion in 2023 after reviewing to be had analysis on GLP-1s.
Pancreatic most cancers used to be some other fear. Right here, too, researchers discovered no constant higher possibility from taking GLP-1 medication in a 2025 research of information from 62 research.
The peace of mind is actual however provisional. Those medication are younger, and most cancers can take a long time to floor.
The most cancers tale activates its head
GLP-1 medication, as soon as scrutinized for perhaps inflicting most cancers, at the moment are being mentioned as medication that may save you and even deal with most cancers.
A 2024 find out about of greater than 1.6 million folks with Sort 2 diabetes discovered decrease charges of 10 out of 13 obesity-related cancers in folks handled with a GLP-1 drug in comparison to insulin.
A 2025 find out about of about 87,000 adults discovered that total most cancers charges amongst those that began a GLP-1 drug have been more or less 17% decrease, with the clearest discounts in endometrial and ovarian cancers in addition to a kind of mind most cancers known as meningioma. The chance of kidney most cancers used to be 38% upper amongst sufferers taking GLP-1 medication, despite the fact that greater research are had to verify its importance.
Research at the hyperlink between GLP-1 medication and diminished most cancers possibility have raised a lot hobby.
A 2026 find out about of greater than 110,000 ladies present process breast imaging discovered a more or less 30% decrease possibility of breast most cancers amongst those that use GLP-1 medication in comparison to those that don’t.
Researchers also are learning how GLP-1 medication have an effect on a affected person’s possibilities of surviving most cancers. Amongst greater than 6,800 colon most cancers sufferers in a 2024 find out about, round 16% of the 103 on a GLP-1 drug died inside of 5 years in comparison to 37% of those that weren’t taking one. A find out about introduced on the 2026 American Society of Medical Oncology reported a 34% decrease possibility of dying throughout six most cancers sorts for the ones taking GLP-1 medication.
Why the proof is very easy to misinterpret
Whilst those findings are thrilling, research at the results of GLP-1 medication on most cancers possibility have 3 options that cause them to particularly simple to misinterpret.
The primary is wholesome person bias. Individuals who get started a GLP-1 drug have a tendency to be fitter and wealthier than those that don’t. An individual with weight problems who has insurance coverage, sees medical doctors incessantly and will come up with the money for Ozempic is a long way much more likely to begin the drug than somebody with the similar peak and weight who lacks the ones benefits.
Wholesome person bias could be very tough to clean out of observational research, which examine folks as they’re handled in actual existence somewhat than assigning the drug at random. The very benefits that made it imaginable to obtain a GLP-1 prescription, no longer the drug itself, could also be what diminished a affected person’s most cancers possibility.
The second one is the collection of the comparability drug. To know the impact of a drug, it needs to be measured in opposition to one thing else. What it’s measured in opposition to will form the result of the find out about. The 2024 find out about reported that sufferers taking GLP-1 medication noticed massive discounts in most cancers possibility in comparison to the ones taking insulin. However evaluating sufferers on GLP-1 medication with sufferers taking the diabetes drug metformin confirmed no transparent aid in most cancers possibility.
Insulin is reserved for sufferers with extra complicated diabetes, a situation this is itself a possibility issue for most cancers. In those research, sufferers on insulin get started out with a better possibility of most cancers. Measured in opposition to a bunch at upper possibility of creating most cancers, nearly anything else can glance protecting. The plain receive advantages got here from the comparability drug, no longer the GLP-1 drug.
The 3rd is timing. It isn’t such a lot some other supply of bias as a clue that different biases could also be at paintings. Most cancers can take a long time to increase, but maximum GLP-1 research stick to folks for just a handful of years. In some research, the obvious most cancers advantages of GLP-1 medication display nearly instantly. However prevention doesn’t paintings that briefly. A drug that really diminished the danger of creating most cancers would display its impact progressively as fewer tumors floor through the years, no longer throughout the first few months of taking a drug.
When most cancers possibility seems to drop nearly once a affected person begins remedy, the velocity isn’t a paranormal triumph of GLP-1 medication. Slightly, individually, it’s the inform: Individuals who get started those medication have been already at decrease most cancers possibility, and the GLP-1 medication are getting credit score for that preexisting benefit.
Additionally, nearly all of this analysis comes from a handful of high-income nations, at the same time as uptake of those medication is expanding globally and the load of most cancers has disproportionately grown in lower-income nations. The concept that GLP-1s would possibly cut back most cancers possibility for far of the arena is being inferred from knowledge generated nearly fully in a couple of wealthy ones.
What do randomized trials display?
The cleanest manner round those find out about biases is randomized trials, which by way of design make comparability teams alike from the beginning.
To be had scientific trials inform a quieter tale than the headlines. Two 2025 meta-analyses, which pool knowledge from more than one research – one masking 50 trials and a 2nd masking 48 – discovered little proof that GLP-1 medication both carry or decrease most cancers possibility.
GLP-1 drug manufacturers abound.
Michael Siluk/UCG/Common Photographs Staff by means of Getty Photographs
The findings of those meta-analyses are normally extra dependable than the ones of observational research as a result of their general quantity of information will increase their statistical energy. In spite of their strengths, those analyses inherit the constraints of the pains they come with. Many of the trials in those 2025 research had a brief follow-up of a yr or two and recorded too few most cancers circumstances to settle the query.
Randomized scientific trials designed to reply to the query of whether or not GLP-1 medication have an effect on most cancers possibility would want to join tens of hundreds of folks and stick to them for a few years. In need of that, the following best possible proof will come from observational research designed to emulate randomized trials.
Till then, the concept GLP-1 medication decrease most cancers possibility is a speculation value checking out however no longer a conclusion to behave on.
The base line
In accordance with the to be had proof, the clearest conclusion is the reassuring one: GLP-1 medication don’t seem to boost total most cancers possibility. On the other hand, extra bold claims that GLP-1s actively save you most cancers or make stronger survival after prognosis stay unproven.
Assume GLP-1s do impact most cancers possibility. Researchers nonetheless would no longer know the place that impact comes from: weight reduction itself, broader growth in metabolic serve as, or a extra direct impact on irritation, the immune gadget or tumors.
The surest factor I will be able to say could also be the least fulfilling: It’s nonetheless too early. Those medication are a long way more youthful than the cancers they’re being credited with fighting.
